Controlling Perioperative Hypertension With Cleviprex Reduces Heart Attack And Death RIsk Following Cardiac Surgery, According To New Analyses
Jun 30th 2008Drug InformationHypertension
The Medicines Company (NASDAQ: MDCO) today announced that data from two post-hoc analyses of the ECLIPSE trial showed that use of Cleviprex? (clevidipine butyrate) injectable emulsion to control blood pressure during cardiac surgery may be associated with a reduced risk of heart attack compared to two of three currently used IV antihypertensive agents. In a separate sub-analysis, Cleviprex was associated with a lower 30-day mortality compared to two nitrovasodilators.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
